Mario Cozzolino, Markus Ketteler, Kevin J. Martin, Amit Sharma, David Goldsmith and Samina Khan
Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving heamodialysis: results of the IMPACT-SHPT study
Nephrol. Dial. Transplant. first published online February 4, 2014 doi:10.1093/ndt/gfu011

Read the article